Showing 5491-5500 of 6035 results for "".
- Armenian EyeCare Project Surpasses Milestone of 10,000 Patients Screened Using Artificial Intelligence Eye Screening Technologyhttps://modernod.com/news/armenian-eyecare-project-surpasses-milestone-of-10000-patients-screened-using-artificial-intelligence-eye-screening-technology/2477088/On this World Diabetes Day, the Armenian EyeCare Project (AECP), a nonprofit organization dedicated to eliminating preventable blindness in Armenia, announced that it has surpassed the milestone of screening 10,000 patients for diabetic retinopathy (DR) throughout Armenia utilizing the state-of-a
- Bausch + Lomb and TerraCycle Announce Donation of New Custom Training Modules to Guide Dog Foundationhttps://modernod.com/news/bausch-lomb-and-terracycle-announce-donation-of-new-custom-training-modules-to-guide-dog-foundation/2477087/Bausch + Lomb in collaboration with TerraCycle, a leader in the collection and repurposing of hard-to-recycle post-consumer waste, announced the donation of custom training modules to the Guide Dog Foundation, a national not-for-profit that trains guide dogs for people who are blind or visually i
- Envision Announces Dates, Calls for Submissions for 2020 Conferenceshttps://modernod.com/news/envision-announces-dates-calls-for-submissions-for-2020-conferences/2477082/Envision announced that it is now accepting submissions for clinical education and research presentations for its two annual conferences in 2020: Envision Conference West, April 3-4, UT Health San Antonio Department of Occupational Therapy in San Antonio, Texas; and Envision Conference East, Augu
- Novaliq and Jiangsu Hengrui Medicine Announce a Collaboration for Investigational NOV03 and CyclASol in Chinahttps://modernod.com/news/novaliq-and-jiangsu-hengrui-medicine-announce-a-strategic-collaboration-in-ophthalmology-for-the-eyesol-based-investigational-products-nov03-and-cyclasol-in-china/2477080/Novaliq and Jiangsu Hengrui Medicine, a biopharmaceutical company based in China, announced the closing of an exclusive license agreement to develop, manufacture and commercialize water-free drugs NOV03 and CyclASol for the treatment of dry eye disease in the People’s Republic of China (including
- Ocular Therapeutix Announces Strategic Update and Operational Restructuringhttps://modernod.com/news/ocular-therapeutix-announces-strategic-update-and-operational-restructuring/2477081/Ocular Therapeutix announced an operational restructuring plan that the company says is expected to result in an estimated $11 million in annualized savings through personnel reductions and approximately $14 million in one-time program deferrals. The company estimates that it will record costs as
- Ocuphire Pharma Announces Results from Two Phase 2 Clinical Studies of Nyxol Eye Dropshttps://modernod.com/news/ocuphire-pharma-announces-results-from-two-phase-2-clinical-studies-of-nyxol-eye-drops/2477075/Ocuphire Pharma announced statistically significant and clinically meaningful results from its recently completed two phase 2b studies of its lead drug candidate, Nyxol Eye Drops. Topline results of the primary and secondary endpoints of the MIRA-1 and ORION-1 studies provided confirmatory
- AGTC Announces Stargardt Disease as its Second Preclinical Ophthalmology Programhttps://modernod.com/news/agtc-announces-stargardt-disease-as-its-second-preclinical-ophthalmology-program/2477071/Applied Genetic Technologies Corporation (AGTC), announced that it has identified Stargardt disease as the second ophthalmology program in its previously announced preclinical pipeline expansion, which also includes a program targeting the dry form of age-related macular degenerat
- Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil in Phase 2 Study Conducted in Japanhttps://modernod.com/news/aerie-pharmaceuticals-announces-positive-topline-results-for-netarsudil-in-phase-2-study-conducted-in-japan/2477069/Aerie Pharmaceuticals reported positive topline results for the company’s phase 2 clinical trial evaluating netarsudil ophthalmic solution in Japanese patients. Netarsudil is a Rho kinase (ROCK) inhibitor specifically designed to increase outflow of aqueous humor through the trabecular meshwork,
- New ECP and Parent Survey Shows the Significant Need for Myopia Educationhttps://modernod.com/news/new-ecp-and-parent-survey-shows-the-significant-need-for-myopia-education/2477070/One in four children in the United States is myopic, but according to The Harris Poll survey results released by CooperVision, only 33% of parents know what that term means,2 or how it can affect their children’s future eyesight. This corroborates the finding that 97% of ECPs agree par
- Allergan Issues Recall for Certain Lots of Xen 45https://modernod.com/news/allergan-issues-recall-for-certain-lots-of-xen-45/2477061/Allergan has initiated a voluntary recall of its XEN 45 glaucoma drainage device after a small number of units in an unreleased lot were observed to have trace amounts of polishing compounds that are used in the needle sleeve manufacturing process, according to a joint news release with ASCRS.